A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma

Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a weekly 24-h infusion in recurrent ovarian carcinoma. In all, 17 patients were recruited and 11 had chemotherapy-resistant disease as defined by disease progression w...

Descripción completa

Detalles Bibliográficos
Autores principales: Clamp, A R, Blackhall, F H, Vasey, P, Soukop, M, Coleman, R, Halbert, G, Robson, L, Jayson, G C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394305/
https://www.ncbi.nlm.nih.gov/pubmed/14520436
http://dx.doi.org/10.1038/sj.bjc.6601285
_version_ 1782155384512839680
author Clamp, A R
Blackhall, F H
Vasey, P
Soukop, M
Coleman, R
Halbert, G
Robson, L
Jayson, G C
author_facet Clamp, A R
Blackhall, F H
Vasey, P
Soukop, M
Coleman, R
Halbert, G
Robson, L
Jayson, G C
author_sort Clamp, A R
collection PubMed
description Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a weekly 24-h infusion in recurrent ovarian carcinoma. In all, 17 patients were recruited and 11 had chemotherapy-resistant disease as defined by disease progression within 4 months of last cytotoxic therapy. All were evaluable for toxicity and 14 for response. There were no disease responses and the main toxicity was myalgia.
format Text
id pubmed-2394305
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23943052009-09-10 A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma Clamp, A R Blackhall, F H Vasey, P Soukop, M Coleman, R Halbert, G Robson, L Jayson, G C Br J Cancer Clinical Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a weekly 24-h infusion in recurrent ovarian carcinoma. In all, 17 patients were recruited and 11 had chemotherapy-resistant disease as defined by disease progression within 4 months of last cytotoxic therapy. All were evaluable for toxicity and 14 for response. There were no disease responses and the main toxicity was myalgia. Nature Publishing Group 2003-10-06 2003-09-30 /pmc/articles/PMC2394305/ /pubmed/14520436 http://dx.doi.org/10.1038/sj.bjc.6601285 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
Clamp, A R
Blackhall, F H
Vasey, P
Soukop, M
Coleman, R
Halbert, G
Robson, L
Jayson, G C
A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma
title A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma
title_full A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma
title_fullStr A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma
title_full_unstemmed A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma
title_short A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma
title_sort phase ii trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394305/
https://www.ncbi.nlm.nih.gov/pubmed/14520436
http://dx.doi.org/10.1038/sj.bjc.6601285
work_keys_str_mv AT clampar aphaseiitrialofbryostatin1administeredbyweekly24hourinfusioninrecurrentepithelialovariancarcinoma
AT blackhallfh aphaseiitrialofbryostatin1administeredbyweekly24hourinfusioninrecurrentepithelialovariancarcinoma
AT vaseyp aphaseiitrialofbryostatin1administeredbyweekly24hourinfusioninrecurrentepithelialovariancarcinoma
AT soukopm aphaseiitrialofbryostatin1administeredbyweekly24hourinfusioninrecurrentepithelialovariancarcinoma
AT colemanr aphaseiitrialofbryostatin1administeredbyweekly24hourinfusioninrecurrentepithelialovariancarcinoma
AT halbertg aphaseiitrialofbryostatin1administeredbyweekly24hourinfusioninrecurrentepithelialovariancarcinoma
AT robsonl aphaseiitrialofbryostatin1administeredbyweekly24hourinfusioninrecurrentepithelialovariancarcinoma
AT jaysongc aphaseiitrialofbryostatin1administeredbyweekly24hourinfusioninrecurrentepithelialovariancarcinoma
AT clampar phaseiitrialofbryostatin1administeredbyweekly24hourinfusioninrecurrentepithelialovariancarcinoma
AT blackhallfh phaseiitrialofbryostatin1administeredbyweekly24hourinfusioninrecurrentepithelialovariancarcinoma
AT vaseyp phaseiitrialofbryostatin1administeredbyweekly24hourinfusioninrecurrentepithelialovariancarcinoma
AT soukopm phaseiitrialofbryostatin1administeredbyweekly24hourinfusioninrecurrentepithelialovariancarcinoma
AT colemanr phaseiitrialofbryostatin1administeredbyweekly24hourinfusioninrecurrentepithelialovariancarcinoma
AT halbertg phaseiitrialofbryostatin1administeredbyweekly24hourinfusioninrecurrentepithelialovariancarcinoma
AT robsonl phaseiitrialofbryostatin1administeredbyweekly24hourinfusioninrecurrentepithelialovariancarcinoma
AT jaysongc phaseiitrialofbryostatin1administeredbyweekly24hourinfusioninrecurrentepithelialovariancarcinoma

Ejemplares similares